[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gdm\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gdm":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,44,66,91,114],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":4},"100643973","advancing-stillbirth-prevention-through-innovative-risk-evaluation-aspire-clinical-study-100643973",false,"NCT07669935","Advancing Stillbirth Prevention Through Innovative Risk Evaluation (ASPIRE) Clinical Study","A Multi-Site, Prospective, Two-Part Longitudinal, Observational Cohort Study Of Pregnant Women To Evaluate Biomarkers For Prediction Of Pregnancy Complications","ASPIRE","Inclusion Criteria:\n\n* Age ≥18 years\n* Nulliparous (no previous births ≥20wk GA)\n* Single viable fetus at the dating ultrasound scan with an ultrasound estimated gestational age of 10 0\u002F7-17 6\u002F7 weeks of gestation\n* Ability to consent and comply with study procedures and follow-up\n\nExclusion Criteria:\n\n* Multiple gestation\n* Inability to provide blood\n* Known fetal chromosomal abnormalities or structural Anomaly (a structural or functional defect with the following three characteristics: 1) of prenatal origin; 2) present at the time of live birth or fetal demise, or in utero; 3) affecting (or has the propensity to affect) the health, survival, or physical or cognitive functioning of the individual\n* Known or anticipated inability to complete study follow-up through delivery at the study site (e.g., planned relocation, transfer of obstetric care to a non-participating institution, or other circumstances making delivery outcome data unavailable)\n* Current or recent (within two months) participation in an interventional clinical study.",true,"FEMALE","18 Years","99 Years",{"count":22,"type":23},5500,"ESTIMATED","OBSERVATIONAL","ASPIRE will be a multi-site, prospective, two-part longitudinal, noninterventional observational cohort study of nulliparous singleton pregnant women to evaluate biomarkers from blood and ocular imaging for prediction of pregnancy complications \\[i.e., preeclampsia (PE), fetal growth restriction (FGR), and gestational diabetes (GDM)\\] and risk of adverse outcomes.",[27,28,29,30,31],"GDM","Preterm Preeclampsia","Preeclampsia","Fetal Growth Restriction (FGR)","Pregnancy Complications","NOT_YET_RECRUITING","2026-06-25",{"date":35,"type":36},"2026-06-29","ACTUAL",{"date":38,"type":23},"2026-07-30",{"date":40,"type":23},"2028-12-01",{"name":42,"class":43},"Medicines360","OTHER",{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":49,"conditions":54,"keywords":4,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":65},"100613194","gestational-lifestyle--outcomes-wellness-100613194","NCT07263412","Gestational Lifestyle & Outcomes Wellness","A Multicenter Prospective Cohort Study to Identify Risk Factors and Develop a Diagnostic Prediction Model for Gestational Diabetes Mellitus, and to Evaluate the Effectiveness of Multidisciplinary Precision Health Interventions (GLOW Plan)","Inclusion Criteria: All must be met\n\n1. Aged 18-40 years;\n2. Pre-pregnancy BMI: 18.5 kg\u002Fm² \\\u003C BMI \\\u003C 28 kg\u002Fm²;\n3. Able to read, understand and sign the informed consent form;\n4. Receive prenatal care and deliver in the study hospital.\n\nExclusion Criteria: Any one met leads to exclusion\n\n1. Twin or multiple pregnancies;\n2. Pre-gestational diabetes mellitus (PGDM), including new-onset diabetes during pregnancy;\n3. Poorly controlled pre-pregnancy chronic hypertension (BP ≥140\u002F90 mmHg);\n4. Complicated with severe liver\u002Fkidney diseases;\n5. Current\u002Frecent use of drugs affecting glucose metabolism;\n6. Mental illness or severe psychological disorders;\n7. Complicated with severe infection;\n8. Poor compliance or refusal to use CGM\u002FSMBG.","40 Years",{"count":53,"type":23},1000,[27],"RECRUITING","2025-11-24",{"date":58,"type":36},"2025-12-04",{"date":60,"type":36},"2025-02-25",{"date":62,"type":23},"2028-11",{"name":64,"class":43},"The First Affiliated Hospital with Nanjing Medical University",1,{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":70,"acronym":4,"eligibilityCriteria":71,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":72,"enrollmentInfo":73,"targetDuration":4,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":80,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":65},"100603796","effect-of-early-lifestyle-intervention-on-perinatal-outcomes-in-high-risk-women-for-gestational-hyperglycemia-100603796","NCT07141173","Effect of Early Lifestyle Intervention on Perinatal Outcomes in High-risk Women for Gestational Hyperglycemia","Inclusion Criteria:\n\n* 18-55 years old\n* 6-14 weeks of pregnancy\n* at least one risk factor for GDM\n* signed a written informed consent\n\nExclusion Criteria:\n\n* Individuals diagnosed with diabetes or prediabetes prior to pregnancy\n* currently taking medications affecting blood glucose levels such as metformin\n* women at risk of miscarriage\n* individuals with chronic conditions (such as uncontrolled hypertension, severe heart disease)\n* those with movement disorders or contraindicated conditions for physical activity\n* patients undergoing gastrointestinal surgeries that alter glucose absorption\n* those unable to maintain regular prenatal care (such as non-compliance with medical instructions or mental health issues).","45 Years",{"count":74,"type":23},604,"INTERVENTIONAL",[77],"NA","This study aims to explore whether early intervention for high-risk groups of gestational hyperglycemia can improve insulin resistance and effectively prevent the occurrence of GDM, and evaluate which pathophysiological subtypes of GDM have the best effect on improving maternal and fetal adverse prognosis, so as to provide evidence for stratified management and individualized clinical intervention of high glucose groups in pregnancy",[27],[27,81],"RCT","2025-08-25",{"date":84,"type":36},"2025-08-26",{"date":86,"type":23},"2025-08-20",{"date":88,"type":23},"2027-08-20",{"name":90,"class":43},"Tianjin Central Hospital of Gynecology Obstetrics",{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":97,"eligibilityCriteria":98,"healthyVolunteers":11,"sex":99,"minAge":4,"maxAge":4,"enrollmentInfo":100,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":102,"conditions":103,"keywords":4,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":65},"100377276","digestnewborn-study-100377276","NCT04192422","DiGESTnewborn Study","Glucose Control and Metabolic Adaptation in Offspring of Women With Gestational Diabetes Recruited to the DiGest Study","DiGESTnewborn","Inclusion Criteria:\n\n* mothers and their babies who have been enrolled in DiGest Trial and who have provided informed consent\n\nExclusion Criteria:\n\n* none","ALL",{"count":101,"type":23},60,"We wish to study the effect of a mothers sugar (glucose) control during pregnancy on her baby's sugar control after birth.",[27,104],"Hypoglycemia","2025-04-15",{"date":107,"type":36},"2025-04-17",{"date":109,"type":36},"2020-09-01",{"date":111,"type":23},"2026-12-31",{"name":113,"class":43},"Cambridge University Hospitals NHS Foundation Trust",{"id":115,"slug":116,"hasResults":11,"nctId":117,"briefTitle":118,"officialTitle":119,"acronym":4,"eligibilityCriteria":120,"healthyVolunteers":17,"sex":99,"minAge":19,"maxAge":121,"enrollmentInfo":122,"targetDuration":4,"studyType":75,"phases":124,"briefSummary":125,"conditions":126,"keywords":4,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":65},"100585394","efficacy-of-lactobacillus-rhamnosus-lra05-in-gestational-diabetes-100585394","NCT06901791","Efficacy of Lactobacillus Rhamnosus LRa05 in Gestational Diabetes","Assessing the Efficacy of Lactobacillus Rhamnosus LRa05 in Improving Blood Glucose and Gut Microbiota in Patients With Gestational Diabetes","Inclusion Criteria:\n\n1. Women diagnosed with gestational diabetes mellitus (GDM) at 24 weeks of gestation.\n\n   Diagnostic criteria for GDM: Abnormal oral glucose tolerance test (OGTT) with an 82.5g glucose load during the 24th week of pregnancy (defined as meeting one or more of the following plasma glucose thresholds: fasting ≥ 5.1 mmol\u002FL, 1-hour ≥ 10 mmol\u002FL, or 2-hour ≥ 8.5 mmol\u002FL).\n2. Pregnant women aged 18 to 50 years.\n3. Singleton pregnancy with a fetus confirmed to be structurally and chromosomally normal via ultrasound or other prenatal diagnostic methods.\n4. No history of chronic diseases, including immune deficiency, hypertension, diabetes, kidney disease, or liver disease.\n5. No consumption of probiotic-containing foods (e.g., yogurt, fermented foods, soybean paste) within the two weeks prior to the study.\n6. Willing and able to provide written informed consent.\n7. Capable of complying with the study protocol and follow-up requirements.\n\nExclusion Criteria:\n\n1. Those who have taken items with similar functions to the test product in the short term, which may affect the judgment of the results.\n2. Those with other endocrine diseases or currently using medications that affect blood glucose control.\n3. Those with severe cardiovascular, kidney, or liver diseases.\n4. Those with immunodeficiency diseases or currently using immunosuppressive agents.\n5. Those with severe gastrointestinal diseases that may affect the absorption or metabolism of probiotics.\n6. Those currently using other medications that may affect blood glucose control or lipid levels.\n7. Those with a history of allergy to probiotics or any components of the study products.\n8. Those with unhealthy lifestyle habits, such as smoking, alcohol consumption, or drug abuse.\n9. Those who do not consume the test samples as required or do not follow up on time, resulting in uncertain efficacy.\n10. Study participants deemed unsuitable by other researchers.","50 Years",{"count":123,"type":23},80,[77],"This study aims to comprehensively evaluate the multifaceted impacts of Lactobacillus rhamnosus LRa05 on patients with gestational diabetes. Initially, the study will investigate the effects of LRa05 on improving patients' blood glucose levels and gut microbiota. Additionally, the study will assess the impact of this strain on patients' blood lipid levels, inflammatory markers, and body mass index (BMI). Furthermore, the study will also focus on its effects on thyroid function, vaginal microbiota, and bile acid metabolism in patients with gestational diabetes.",[27],"2025-03-28",{"date":129,"type":36},"2025-03-30",{"date":131,"type":23},"2025-04-10",{"date":133,"type":23},"2026-03-10",{"name":135,"class":136},"Wecare Probiotics Co., Ltd.","INDUSTRY"]